Physician

Purvi K Shah, M.D.

According to 2025 Medicare claims, Purvi Shah, M.D. (NPI: 1275580722) practices hematology/oncology in the Richmond, VA market, with the plurality of this provider's patient population coming from Henrico, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER INSTITUTE INCORPORATED (NPI: 1730130980; TIN: 54-1066435) and primary practice location at 23229-8605.

Shah's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 700 traditional Medicare patients, billed 127,313 HCPCS/CPT codes, and received $2,556,793 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,418 prescription claims across 191 beneficiaries totaling $3,038,304 in drug costs, led by Revlimid (Lenalidomide). DME data shows 34 claims. Open Payments data shows 136 records totaling $273,907. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,036,770 to $2,556,793. Similarly, Part D prescription costs have moved sharply higher in recent years, from $929,415 to $3,038,304. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	626	142,778	$1,036,770
2016	467	57,762	$440,374
2017	541	40,453	$705,714
2018	884	148,675	$2,046,563
2019	919	195,671	$3,032,041
2020	816	137,764	$2,422,047
2021	736	147,710	$2,605,105
2022	759	139,684	$2,504,007
2023	668	153,481	$3,028,605
2024	700	127,313	$2,556,793

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	123	1,189	$929,415
2016	121	875	$535,602
2017	101	555	$70,873
2018	113	665	$631,174
2019	126	827	$975,227
2020	136	845	$1,047,810
2021	161	1,065	$1,281,609
2022	173	1,153	$1,955,051
2023	177	1,310	$2,269,233
2024	191	1,418	$3,038,304

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	122	$24,864
2016	N/R	23	$797
2017	N/R	55	$12,972
2018	N/R	29	$4,553
2019	N/R	87	$7,853
2020	N/R	54	$3,668
2021	N/R	71	$5,568
2022	N/R	62	$1,950
2023	N/R	104	$19,225
2024	N/R	34	$851

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	149	351	$96
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	209	401	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	124	156	$60
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	166	219	$12
96372	Injection of drug or substance under skin or into muscle	162	357	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	51	1,428	$950,636
Empaveli	Pegcetacoplan	11	308	$440,177
Imbruvica	Ibrutinib	13	364	$241,433
Eliquis	Apixaban	82	2,647	$50,399
Xarelto	Rivaroxaban	46	1,738	$32,402

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	17	$531
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	17	$320

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	108	$2,411	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	28	$271,496	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Purvi K. Shah, M.D.?

Tedicare shows public-source Medicare data for Purvi K. Shah, M.D. (NPI 1275580722), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Purvi K. Shah, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Purvi K. Shah, M.D.?

Purvi K. Shah, M.D. is linked to VIRGINIA CANCER INSTITUTE INCORPORATED (billing NPI 1730130980) in the available physician profile data.

Does Purvi K. Shah, M.D. have Open Payments data?

Purvi K. Shah, M.D. has 136 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.